Tai Sandi See insider trades: Lexeo Therapeutics (LXEO) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Tai reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 18, 2025 | LXEO | ↓ Sell | 386 | $9.27 | $4K | Direct | Nov 20, 2025 (2d) |
| Oct 17, 2025 | LXEO | ↓ Sell | 3,888 | $8.94 | $35K | Direct | Oct 17, 2025 (0d) |
| Aug 18, 2025 | LXEO | ↓ Sell | 382 | $4.67 | $2K | Direct | Aug 20, 2025 (2d) |
| May 16, 2025 | LXEO | ↓ Sell | 367 | $2.77 | $1K | Direct | May 20, 2025 (4d) |
| Feb 19, 2025 | LXEO | ↓ Sell | 1,486 | $4.41 | $7K | Direct | Feb 21, 2025 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other LXEO insiders
Open-market trades in the last 12 months
About Tai Sandi See's insider trades
Tai Sandi See is Chief Development Officer at Lexeo Therapeutics (LXEO). Since Feb 19, 2025, Tai has reported no open-market purchases and 5 sales worth $48K on SEC Form 4. In the last 12 months: 1 sale ($4K).
Their filings also include grants and awards (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LXEO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.